Page last updated: 2024-11-05

alpha-terpineol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alpha-terpineol is a naturally occurring monoterpene alcohol found in many essential oils, such as pine, lavender, and tea tree oil. It is a colorless liquid with a floral, woody, and slightly citrusy odor. Alpha-terpineol is used in various applications, including fragrances, cosmetics, and pharmaceuticals. It has been studied for its potential therapeutic properties, including its antimicrobial, anti-inflammatory, and antioxidant effects. It is also used as a flavoring agent in foods and beverages. Alpha-terpineol is synthesized from pinene, a major component of turpentine oil. It can also be produced by fermentation using microorganisms.'

terpineol : A family of monoterpenols that have a p-menthane skeleton containing one double bond and bearing a single hydroxy substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID17100
CHEMBL ID449810
CHEBI ID22469
SCHEMBL ID28466
MeSH IDM0066974

Synonyms (134)

Synonym
AKOS015840815
3-cyclohexene-1-methanol, .alpha.,.alpha.4-trimethyl-
terpineol
(+)-.alpha.-terpineol
menth-1-en-8-ol
.alpha.-terpineol
nsc-21449
p-menth-1-en-8-ol
terpineol schlechthin
terpineol, alpha
98-55-5
nsc21449
3-cyclohexene-1-methanol,.alpha.4-trimethyl-
alpha-terpineol ,
C0669
dl a-terpineol
1-methyl-4-isopropyl-1-cyclohexen-8-ol
alpha,alpha,4-trimethyl-3-cyclohexene-1-methanol
2-(4-methyl-3-cyclohexenyl)-2-propanol
1-p-menthen-8-ol
3-cyclohexene-1-methanol, .alpha.,.alpha.,4-trimethyl-
dl-alpha-terpineol
fema no. 3045
terpineol 350
alpha-terpineol (natural)
hsdb 5316
3-cyclohexene-1-methanol, alpha,alpha,4-trimethyl-
terpilenol, alpha-
alpha-terpinenol
(1)-alpha,alpha,4-trimethylcyclohex-3-ene-1-methanol
einecs 219-448-5
terpenol
brn 1906604
einecs 202-680-6
nsc 21449
ai3-00275
ccris 3204
pc 593
fema number 3045
3-cyclohexene-1-methanol, .alpha.,.alpha.,4-trimethyl-, (s)-
nsc-403665
nsc403665
carvomenthenol
alpha-terpineol, 90%, technical grade
1-menthene-8-ol
1-methyl-4-isopropyl-1-cyclohexene-8-ol
NCGC00164431-01
2-(4-methylcyclohex-3-en-1-yl)propan-2-ol
CHEBI:22469 ,
1-alpha-terpineol
terpineols
68797-63-7
T0022
T0984
NCGC00248528-01
einecs 232-268-1
epa pesticide chemical code 067005
caswell no. 823
ec 232-268-1
r53q4zwc99 ,
8006-39-1
unii-r53q4zwc99
dsstox_gsid_40775
tox21_302298
NCGC00255464-01
dsstox_cid_6625
cas-8000-41-7
dsstox_rid_79596
cas-98-55-5
tox21_200112
NCGC00257666-01
tox21_112118
dtxsid5026625 ,
dtxcid406625
CHEMBL449810
2-(4-methyl-1-cyclohex-3-enyl)-propan-2-ol
21334lvv8w ,
unii-21334lvv8w
ec 202-680-6
FT-0627680
FT-0622202
2-(4-methylcyclohex-3-enyl)propan-2-ol
terpene alcohol
alpha-terpineol [fcc]
terpin monohydrate impurity a [ep impurity]
.alpha.-terpineol [mi]
.alpha.-terpineol [fhfi]
alfa-terpineol
3-cyclohexene-1-methanol, alpha., .alpha., 4-trimethyl-
alpha-terpineol [hsdb]
mil-350
alfa-terpineol [who-dd]
.alpha.-terpineol [ii]
pc-593
.alpha.terpineol
SCHEMBL28466
3-cyclohexene-1-methanol, .alpha.,.alpha.,4-trimethyl-, sodium salt, (1s)-
J-500272
(1r)-a,a,4-trimethyl-3-cyclohexene-1-methanol
W-100076
FT-0698995
mfcd00001557
mfcd00075926
alpha-terpineol, aldrichcpr
SR-01000944873-1
sr-01000944873
alpha-terpineol, analytical standard
alpha-terpineol, primary pharmaceutical reference standard
-terpineol
+/--terpineol 1000 microg/ml in n-hexane
22347-88-2
F0001-2319
FT-0772029
HY-N5142
Q27109437
D70165
CS-0032554
SB45068
alfa_terpineol
EN300-125883
SY117295
(s)-2-(4-methyl-3-cyclohexen-1-yl)-2-propanol
menthen-8-ol
1-p-menthen-8-
alpha -terpineol
Z1255427148
alpha-terpineol 1000 microg/ml in acetone
alphaterpineol
usepa/opp pesticide code: 067003
flavor and extract manufacturers' association no. 3045
3-cyclohexene-1-methanol, alpha, alpha, 4-trimethyl-
terpin monohydrate impurity a (ep impurity)
3-cyclohexene-1-methanol, alpha., alpha, 4-trimethyl-
alpha-terpineol (ii)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The essential oil had a significant toxic effect against early fourth stage larvae of Aedes aegypti L with an LC(50) value of 28."( Immunotoxicity activity of the major essential oil of Filipendula glaberrima against Aedes aegypti L.
Lee, SJ; Moon, HI, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dose-response experiments revealed that exposure of the cells to a 2- or 4-fold concentrated AD resulted in an increased IL-6 formation, whereas an inhibiting effect was measured after treatment of the cells with an 8-fold concentrated AD."( Characterization of alpha-terpineol as an anti-inflammatory component of orange juice by in vitro studies using oral buccal cells.
Held, S; Schieberle, P; Somoza, V, 2007
)
0.66
" In this study we applied TTO in its pure form and as a 20% solution in ethanol in vitro to human epidermal membranes from three different donors, mounted in horizontal Franz-type diffusion cells, using normal 'in use' dosing conditions (10 mg/cm2)."( Human skin penetration of the major components of Australian tea tree oil applied in its pure form and as a 20% solution in vitro.
Cross, SE; Roberts, MS; Russell, M; Southwell, I, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
terpineolA family of monoterpenols that have a p-menthane skeleton containing one double bond and bearing a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.00310.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency38.78690.000714.592883.7951AID1259369
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency13.44810.000214.376460.0339AID720691
pregnane X nuclear receptorHomo sapiens (human)Potency54.81530.005428.02631,258.9301AID1346982
lamin isoform A-delta10Homo sapiens (human)Potency0.00350.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency76.95880.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1348560Anti-asthmatic activity in ovalbumin-induced asthmatic Sprague-Dawley rat model assessed as IL-17 levels in serum at 1 g/kg, po co-administered with OVA from day 15 to 21 of experiment period (Rvb = 16.85 +/- 1.13 pg/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1348547Anti-asthmatic activity in guinea pig tracheal smooth muscle ring assessed as reduction in acetylcholine-induced muscle contractions by measuring muscle relaxation at 1.25 mmol/l after 60 mins (Rvb = 13.59 +/- 9.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1348554Anti-asthmatic activity in ovalbumin-induced asthmatic Sprague-Dawley rat model assessed as improvement in lung function by measuring dynamic compliance of the airway at 1 g/kg, po co-administered with OVA from day 15 to 21 of experiment period (Rvb = 0.42018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1348557Anti-asthmatic activity in ovalbumin-induced asthmatic Sprague-Dawley rat model assessed as IL-14 levels in serum at 1 g/kg, po co-administered with OVA from day 15 to 21 of experiment period (Rvb = 16.04 +/- 1.41 pg/ml)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1348555Anti-asthmatic activity in ovalbumin-induced asthmatic Sprague-Dawley rat model assessed as improvement in lung function by measuring airway resistance at 1 g/kg, po co-administered with OVA from day 15 to 21 of experiment period (Rvb = 67.33 +/- 10.54 No2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1612115Sedative effect in Swiss mouse assessed as reduction in motility at 34 nM2018European journal of medicinal chemistry, Sep-05, Volume: 157Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus.
AID1348549Agonist activity at beta-adrenergic receptor in rat airway smooth muscle cells assessed as reduction in acetylcholine-induced muscle contractions by measuring cAMP levels after 18 hrs post acetylcholine stimulation by ELISA (Rvb = 8.402 +/- 0.041 nmol/l)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1348546Anti-asthmatic activity in guinea pig tracheal smooth muscle ring assessed as reduction in acetylcholine-induced muscle contractions by measuring muscle relaxation at 0.75 mmol/l after 60 mins (Rvb = 7.73 +/- 4.81%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1612097Antimicrobial activity against Candida albicans2018European journal of medicinal chemistry, Sep-05, Volume: 157Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus.
AID1551058Positive allosteric modulation of recombinant human GABAA alpha1beta2gamma2s receptor expressed in Xenopus laevis oocytes assessed as GABA-stimulated current amplitude at 300 uM measured for 2 min by electrophysiological method relative to control2019European journal of medicinal chemistry, Jun-01, Volume: 171GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators.
AID1612095Antibacterial activity against Escherichia coli CMCC 44102 after 24 hrs by broth dilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus.
AID1348548Anti-asthmatic activity in guinea pig tracheal smooth muscle ring assessed as reduction in acetylcholine-induced muscle contractions after 60 mins2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1612096Antimicrobial activity against Gardnerella vaginalis2018European journal of medicinal chemistry, Sep-05, Volume: 157Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (208)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (2.88)18.7374
1990's9 (4.33)18.2507
2000's53 (25.48)29.6817
2010's107 (51.44)24.3611
2020's33 (15.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.49 (24.57)
Research Supply Index5.37 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index83.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.47%)5.53%
Reviews8 (3.76%)6.00%
Case Studies2 (0.94%)4.05%
Observational0 (0.00%)0.25%
Other202 (94.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]